MEDICAL ONCOLOGY

Abbrev. Title

AK112-101

Protocol Title

A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumours

AK112-101

A Phase 1/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Select Advanced Solid Tumours

AK114-102

A Phase 1a, Multicentre, Open Label, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Anti Tumour Activity of AK114 in Subjects with Advanced or Metastatic Solid Tumours

AK127-101

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK127 in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumours

AL-DES-01 RINGSIDE A Phase 2/3, Randomised, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumours

ANZUP1801 DASL-HiCaP

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer

ANZUP1801 DASL-HiCaP Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer

ANZUP1802 UniCAB A Phase II Trial of Single Agent Cabozantinib in Patients with Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy or who are Unsuitable for Immunotherapy

AT148003 ASPEN-03 A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma

AT148004 ASPEN-04 A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma